This article was automatically generated by MarketWatch using technology from Automated Insights.
Shares of Incyte Corp. (INCY) slipped 1.20% to $97.63 Thursday, on what proved to be an all-around positive trading session for the stock market, with the S&amp;P 500 Index rising 0.77% to 7,501.24 and the Dow Jones Industrial Average rising 0.75% to 50,063.46.
This was the stock's third consecutive day of losses.
Incyte Corp. closed 13.06% below its 52-week high of $112.29, which the company achieved on January 7th.
The stock underperformed when compared to some of its competitors Thursday, as Alnylam Pharmaceuticals Inc. (ALNY) rose 0.68% to $293.45, Bio-Techne Corp. (TECH) fell 0.33% to $44.74, and BioMarin Pharmaceutical Inc. (BMRN) fell 0.58% to $53.24.
Trading volume (1.4 M) remained 152,848 below its 50-day average volume of 1.5 M.
Data source: Dow Jones Market Data, FactSet. Data compiled May 14, 2026.
This content was created by MarketWatch, which is operated by Dow Jones &amp; Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
05-14-26 1707ET

INCY

LABU

Incyte Corp. (INCY) shares fell 1.20% to $97.63 on Thursday, marking the third consecutive day of losses, despite a positive trading session for the overall market. The S&P 500 rose 0.77%, while Incyte's stock is now 13.06% below its 52-week high of $112.29. Competitors like Alnylam Pharmaceuticals saw a rise of 0.68%, while Bio-Techne and BioMarin experienced slight declines. Trading volume was below the 50-day average.

MarketWatch Automated

Incyte

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

Health Care Select Sector SPDR

SPDR S&P Biotech

iShares Global Healthcare

First Trust NYSE Arca Biotech Index Fd

VG Health

Proshares Ultra Nasdaq Biotech

iShares US Pharma

Ark Genomic Revolution ETF

iShares Biotechnology ETF

VanEck Biotech ETF

S&P 500

Dow Jones Industrial Average

Alnylam Pharma

Bio-Techne

BioMarin Pharma

Factset Research

Incyte Corp. Stock Underperforms Thursday When Compared To Competitors